Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

Abstract Purpose This post hoc analysis evaluated attainment of diabetes-related composite quality measures (CQMs) with canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg in patients with type 2 diabetes mellitus (T2DM). We used pooled data from two 52-week Phase III clinical trials...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2015-05, Vol.37 (5), p.1045-1054
Hauptverfasser:	Bailey, Robert A., MD, Vijapurkar, Ujjwala, PhD, Meininger, Gary, MD, Rupnow, Marcia F.T., PhD, Blonde, Lawrence, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Pressure - drug effects Body Mass Index canagliflozin Canagliflozin - administration & dosage Canagliflozin - adverse effects Canagliflozin - therapeutic use Clinical trials composite quality measures Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Dose-Response Relationship, Drug Female Glucosides - adverse effects Glycated Hemoglobin - metabolism Health care policy Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Internal Medicine Male Medical Education Middle Aged Obesity Patients Pay for performance Pyrazines - adverse effects quality measures Randomized Controlled Trials as Topic sitagliptin Sitagliptin Phosphate - adverse effects Sitagliptin Phosphate - therapeutic use T2DM Thiophenes - therapeutic use Triazoles - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!